LINVEK is a modern antidiabetic formulation designed to provide effective and consistent blood glucose control in patients with type 2 diabetes mellitus.
It works by enhancing the body’s natural incretin system, helping regulate insulin secretion and reduce glucose levels without causing significant hypoglycemia.
Formulated for once-daily use, LINVEK ensures convenience, safety, and patient compliance in long-term diabetes management.
Effective glycemic control with enhanced safety and compliance
Improves glycemic control in type 2 diabetes
Low risk of hypoglycemia when used appropriately
Weight-neutral therapy
Once-daily dosing for better compliance
Suitable for long-term use
Does not require dose adjustment in renal impairment
Linagliptin is a DPP-4 inhibitor that increases incretin hormone levels, leading to enhanced insulin secretion (when glucose is high), reduced glucagon release, and better overall blood sugar regulation.
LINVEK is indicated for improving glycemic control in patients with type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents.